Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer

Sanne C. F. A. Huijberts, Robin M. J. M. van Geel, Rene Bernards, Jos H. Beijnen, Neeltje Steeghs

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)161-174
Number of pages14
JournalFuture Oncology
Volume16
Issue number6
DOIs
Publication statusPublished - Feb 2020

Keywords

  • binimetinib
  • BRAF inhibitor
  • BRAFV600E mutation
  • cetuximab
  • colorectal cancer
  • EGFR inhibitor
  • encorafenib
  • MEK inhibitor
  • metastatic
  • BRAF MUTATION STATUS
  • BRAF(V600E) INHIBITION
  • ANTITUMOR-ACTIVITY
  • DOSE-ESCALATION
  • MEK INHIBITION
  • COLON-CANCER
  • PHASE IB
  • RESISTANCE
  • VEMURAFENIB
  • EGFR

Cite this